News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma to present the Phase IIb PLIANT study data at ASCO 2016

May 19, 2016

PledPharma AB
Company Announcement

PledPharma to present the Phase IIb PLIANT study data at ASCO 2016

Stockholm, 2016-05-19 08:18 CEST (GLOBE NEWSWIRE) -- 
PledPharma to present the Phase IIb PLIANT study data confirming
chemotherapy-induced nerve damage reducing effects of PledOx® at ASCO 2016 

PledPharma announced today that it will present the results from the Phase IIb
PLIANT clinical study of PledOx® - a potential new drug to reduce nerve damage
associated with chemotherapy – at the upcoming ASCO Annual Meeting in Chicago. 

The data will be presented in a Poster Discussion Session entitled "Patient and
Survivor Care", on June 6, 2016 by the study's principal investigator,
Professor Bengt Glimelius. 

"The fact that the results from the PLIANT clinical study have been selected
for presentation at ASCO underlines the growing interest that leading
oncologists have been showing in PledOx®, which has the potential to reduce the
major problem of chemotherapy induced nerve damage," says Jacques Näsström,
CEO, PledPharma. 

"Chemotherapy induced nerve damage can be very troublesome as well as
persistent and I look forward to the opportunity to present and discuss, these
positive PledOx® results, with leading international oncologists at the
upcoming ASCO Annual Meeting in Chicago," says Bengt Glimelius, emeritus
professor of oncology at the University of Uppsala and principal investigator
of the PLIANT study. 

In the Phase IIb clinical study, PLIANT patients were treated with PledOx® in
order to reduce the risk of nerve damage associated with chemotherapy in
advanced colorectal cancer with oxaliplatin. The study results showed a
statistically significant and clinically relevant reduction in the incidence
and severity of chemotherapy induced peripheral neuropathy compared to placebo.
It was also observed that PledOx® does not negatively interfere with the
anti-cancer effect of chemotherapy. Symptoms of nerve damage often lead to dose
reduction of the chemotherapy or premature discontinuation of therapy. 

PledPharma’s presentation at the Poster Discussion Session is based on the
abstract "Persistent Prevention of CIPN Using Calmangafodipir (PledOx): Results
from a Placebo-Controlled Randomized Phase II Study (PLIANT) in Patients with
Metastatic Colorectal Cancer (mCRC)", which is available on the ASCO website and on 

For more information, please contact:

Jacques Näsström, CEO, phone: +46 737 130 979

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma

PledPharma develop new drugs that protect the body against oxidative stress - a
potentially disabling and sometimes life-threatening condition that can be
caused by chemotherapy and acetaminophen poisoning. The company's most advanced
project PledOx® reduces nerve damage associated with chemotherapy. Positive
results from phase IIb study PLIANT were presented in the spring of 2015. The
drug candidate Aladote® is developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. The project PP-099 aims to limit the
damage that occurs to the heart muscle during a heart attack. PledPharma
(STO:PLED) is listed on Nasdaq First North. Erik Penser Bank is the Certified
Adviser. For further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10